Impurity study of tecovirimat

• Published in: Heliyon Vol. 10; no. 9; p. e29559
• Main Authors: Bonku, Emmanuel Mintah, Qin, Hongjian, Odilov, Abdullajon, Abduahadi, Safomuddin, Desta Guma, Samuel, Yang, Feipu, Xing, Xinglong, Wang, Xukun, Shen, Jingshan
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 15.05.2024; Elsevier
• Subjects: Genotoxic impurities; International Conference on Harmonization (ICH); Process development; Quality control; Tecovirimat; Tecovirimat; Process development; Genotoxic impurities; International Conference on Harmonization (ICH); Quality control
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2024.e29559

This article delineates the systematic identification, synthesis, and impurity control methods used during the manufacturing process development of tecovirimat, an antiviral drug that treats monkeypox. Critical impurities were synthesized, and their chemical structure was confirmed through NMR analysis, GC, and HPLC mass spectrometry. The results established a thorough approach to identify, address, and control impurities to produce high-quality tecovirimat drug substance in accordance with International Conference on Harmonization (ICH)-compliant standards. This study is the first of its kind to evaluate both process and genotoxic impurities in tecovirimat, demonstrating effective control measures during commercial sample investigations and scaling up to a 60-kg batch size. The findings highlight the importance of critical impurity characterization and control in pharmaceutical development and production to ensure the safety and efficacy of the final product.